# GB-115

Dipeptide-like CCK-receptor blocker; daytime anxiolytic without sedation or blunting.

- Page: https://peprank.xyz/peptides/gb-115
- Category: Mood & anxiety (Research peptide)
- Also known as: Ranquilon; 6-phenylhexanoyl-glycyl-L-tryptophan amide
- Routes: Nasal / Sublingual / Oral
- Sequence: GW (N-(6-phenylhexanoyl)-Gly-Trp amide; CCK-4 derived anxiolytic dipeptide)
- Safety tier: Strict: Caution · Balanced: Clean · Evidence only: Clean
- Risk axes (0 none to 3 severe): Seen harm 0, Mechanism 1, Data gap 1, Silent harm 1, Product 2
- Positive: 57% of 41 graded reports glowing or positive, shrunk toward the 49% all-report average by 8 reports' weight
- Rank: #3 of 61 research peptides
- Graded reports: 41 (Glowing 9, Positive 15, Mixed 6, Nothing 7, Negative 2, Bad reaction 2)
- Evidence: Approved drug — in Russia as Ranquilon; open randomized phase IV trial (2026, n=200) beat fabomotizole on anxiety response (63% vs 49%), mild side effects only. Earlier: uncontrolled pilot in 31 GAD patients.
- Access: Grey market
- Onset: Some feel it from the first doses; most users and the trials put clear anxiolysis at 1-2 weeks of daily use, still building to about 4 weeks.
- Lasts: Roughly 3-5 hours per nasal dose; daily users describe a steady background effect rather than peaks.
- Cost per month: ≈ €22–54 (researchers' estimate)
- Updated: 2026-10-30

## What users report

Enthusiastic r/NooTopics reports: lower GAD and rumination, 'vacation feeling', no sedation, often after 1-2 weeks of daily use. Fewer threads than Selank and a vendor (Everychem) drives much of the discussion, so treat with some caution; perhaps 25-35% feel little.

**Effects:** less rumination about the future; reduced general anxiety; mild mood lift; no sedation or cognitive dulling

**Downsides:** nasal burning (spray); slow onset (1-2 weeks); vertigo after months of use (isolated report); short duration (~4 h)

**Caveat:** Strictly a peptidomimetic, not a classic peptide. No known harm mechanism, but the evidence base is thin and mostly from the developer institute.

**Typical use:** 2-6 mg/day sublingual/oral in divided doses (clinical pilot used 1-6 mg), or 3-5 sprays/day; cycle after a few months.

**Getting it:** Approved in Russia as Ranquilon tablets; elsewhere research-chemical nasal sprays, oral solutions and powder.

**Stacked with:** Selank or NA-Selank (The most discussed pairing for anxiety, used together or situationally.); Modafinil or flmodafinil (Several severe-anxiety users say the combination leaves them energized and able to go out without the stimulant's jitters.); ACD-856 (A common r/NooTopics combination for anxiety plus mood and drive; users note it is hard to tell which compound does what.)

## Risk profile

- **Seen harm 0/3:** A 220-patient double-blind phase III trial and a 200-patient open phase IV trial report only mild adverse events and no SAEs, and the forty first-hand reports describe throat burning, hours of disorientation and vertigo after months, none serious.
- **Mechanism 1/3:** A central CCK-1 receptor antagonist (a dipeptide peptidomimetic) with anxiolytic action; no pathway to serious harm has been described, though the Russian label lists a reversible drop in visual acuity and proteinuria among its adverse reactions.
- **Data gap 1/3:** Approved in Russia as Ranquilon since 2023, with a 220-patient placebo-controlled trial, a 200-patient open trial and small pilots, all four weeks or shorter and co-authored by the developer or manufacturer.
- **Silent harm 1/3:** Reported harms (sedation, disorientation, vertigo) are noticeable and resolved on stopping.
- **Product 2/3:** Outside Russia it is research-chemical nasal spray, oral solution or powder.
- **Never if:** Pregnancy or breastfeeding (label); Under 18 (label)

## Top reports

- Glowing, anxiety: “Ive tried countless nootropics/drugs in attempt to settle my anxiety without sedation or cognitive/emotional dulling. GB115 not only does that but also subtly uplifts my mood.” — [r/NooTopics](https://www.reddit.com/r/NooTopics/comments/1s8c9lk/my_review_of_gb115/)
- Glowing, anxiety, 1 spray per nostril: “The only thoughts in my head were/are relevant, not ruminating. I can do the hard things if I want. (Never could before without extreme stress and anxiety)” — [r/NooTopics](https://www.reddit.com/r/NooTopics/comments/1q1e4cl/gb115_day_7/)
- Glowing, anxiety: “This is the first thing, in 20 years, I’ve taken for GAD that I haven’t felt “I should have just taken my benzo.” I actually have relief.” — [r/NooTopics](https://www.reddit.com/r/NooTopics/comments/1kavggk/gb115_benzodiazepines_are_over_everychem_agenda/mqst65b/)
- Glowing, anxiety, 1 spray per nostril each morning: “I’ll just be going about my day as usual and I’ll suddenly notice the background fear and worry just isn’t there, or it’s greatly diminished.” — [r/NooTopics](https://www.reddit.com/r/NooTopics/comments/1pghvoj/when_to_expect_anxiolytic_effects_from_gb115/nt0q5k7/)
- Glowing, anxiety, 6 mg: “I did 6mg GB-115 and 200mg modafinil and HOLYshit it worked the best for my severe anxiety.” — [r/NooTopics](https://www.reddit.com/r/NooTopics/comments/1sbmvdr/gb115_modafinil/)

## Studies

- [Karavayeva et al.: Ranquilon vs Afobazol in anxiety with neurasthenia and adjustment disorders (open randomized phase IV)](https://pubmed.ncbi.nlm.nih.gov/42565399/) (rct, n=200, 2026): GB-115 (Ranquilon) 6 mg/day for 28 days gave more 50% HARS responders than fabomotizole (63% vs 49%), with only mild side effects.
- [Neznamov et al.: Results of a clinical study of a new anxiolytic, a blocker of central cholecystokinin receptors](https://pubmed.ncbi.nlm.nih.gov/31626171/) (open-label, n=31, 2019): In GAD the effective dose was 6 mg/day, with fast anxiolysis, mild stimulation, better sleep and attention, and good tolerability.
- [Dorofeeva et al.: Clinical effects of central antagonist of cholecystokinin-1 receptors GB-115 in patients with GAD (post-hoc)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9564032/) (open-label, n=25, 2022): Over 21 days median HARS fell from 22 to 5 and fatigue (MFI-20) from 70 to 28, with no stimulation-related side effects.
- [Panchenko et al.: GB-115 and phenazepam on the behavior of rhesus monkeys under isolation](https://pubmed.ncbi.nlm.nih.gov/39847298/) (animal, n=4, 2025): Oral GB-115 eased isolation-stress behavior and lowered the cortisol/DHEA-S ratio in monkeys, comparable to phenazepam.
- [Kolik et al.: Anxiolytic activity of dipeptide GB-115 after oral administration](https://pubmed.ncbi.nlm.nih.gov/24130989/) (animal, 2013): Oral GB-115 was anxiolytic in outbred and BALB/c mice in the open-field and elevated plus-maze tests.

## Sources

- [Zakusov Institute 2019: clinical study of GB-115 in anxiety disorders (PubMed 31626171)](https://pubmed.ncbi.nlm.nih.gov/31626171/)
- [Post-hoc analysis of GB-115 in GAD, European Psychiatry 2022](https://pmc.ncbi.nlm.nih.gov/articles/PMC9564032/)